uniQure N.V.

NASDAQ:QURE

17.73 (USD) • At close December 26, 2024
Bedrijfsnaam uniQure N.V.
Symbool QURE
Munteenheid USD
Prijs 17.73
Beurswaarde 864,215,163
Dividendpercentage 0%
52-weken bereik 3.73 - 18.12
Industrie Biotechnology
Sector Healthcare
CEO Mr. Matthew Craig Kapusta
Website https://www.uniqure.com

An error occurred while fetching data.

Over uniQure N.V.

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a

Vergelijkbare Aandelen

POINT Biopharma Global Inc. logo

POINT Biopharma Global Inc.

PNT

12.5 USD

Cross Country Healthcare, Inc. logo

Cross Country Healthcare, Inc.

CCRN

18 USD

SIGA Technologies, Inc. logo

SIGA Technologies, Inc.

SIGA

6.06 USD

Design Therapeutics, Inc. logo

Design Therapeutics, Inc.

DSGN

6.49 USD

Erasca, Inc. logo

Erasca, Inc.

ERAS

2.62 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

0.266 USD

Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc.

RCKT

12.02 USD

Evolus, Inc. logo

Evolus, Inc.

EOLS

11.35 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)